Stay updated on KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial
Sign up to get notified when there's something new on the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page.

Latest updates to the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page
- CheckyesterdayChange DetectedA new revision (v3.6.0) has been added to the study history and the previous revision (v3.5.5) has been removed; the recruitment status now shows that the study is no longer enrolling participants.SummaryDifference0.3%

- Check9 days agoChange DetectedThe history now includes a new Revision: v3.5.5 entry, and the prior Revision: v3.5.4 entry is removed, indicating an updated version of the page. This reflects a new release in the page’s record history.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe record history now shows a new revision (v3.5.4) replacing the previous (v3.5.3). This reflects an update to the page's revision-tracking data.SummaryDifference0.1%

- Check44 days agoChange DetectedThe revision tag on the page history updated from v3.5.2 to v3.5.3, indicating a new release of the page's history metadata.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 in the record history. This reflects a version change in the page’s interface rather than substantive trial data.SummaryDifference0.1%

- Check73 days agoChange DetectedThe sponsor field was updated from 'Karuna Therapeutics' to 'Karuna Therapeutics, Inc., a Bristol Myers Squibb company' to reflect the full corporate affiliation.SummaryDifference0.2%

Stay in the know with updates to KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT Efficacy in Acute Schizophrenic Patients Clinical Trial page.